WO2008130551A3 - Antibiotic resistance free listeria strains and methods for constructing and using same - Google Patents

Antibiotic resistance free listeria strains and methods for constructing and using same Download PDF

Info

Publication number
WO2008130551A3
WO2008130551A3 PCT/US2008/004861 US2008004861W WO2008130551A3 WO 2008130551 A3 WO2008130551 A3 WO 2008130551A3 US 2008004861 W US2008004861 W US 2008004861W WO 2008130551 A3 WO2008130551 A3 WO 2008130551A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
listeria strains
constructing
same
antibiotic resistance
Prior art date
Application number
PCT/US2008/004861
Other languages
French (fr)
Other versions
WO2008130551A2 (en
Inventor
Yvonne Paterson
Thorsten Verch
Original Assignee
Univ Pennsylvania
Yvonne Paterson
Thorsten Verch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/785,249 external-priority patent/US7855064B2/en
Priority claimed from US11/818,965 external-priority patent/US7858097B2/en
Application filed by Univ Pennsylvania, Yvonne Paterson, Thorsten Verch filed Critical Univ Pennsylvania
Priority to EP08742912A priority Critical patent/EP2147092A4/en
Priority to JP2010504068A priority patent/JP2010534058A/en
Publication of WO2008130551A2 publication Critical patent/WO2008130551A2/en
Publication of WO2008130551A3 publication Critical patent/WO2008130551A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides Listeria strains that express a heterologous antigen, a metabolic enzyme, and a phage integrase and use of such Listeria strains in methods of inducing an immune response to an antigen of interest.
PCT/US2008/004861 2007-04-16 2008-04-15 Antibiotic resistance free listeria strains and methods for constructing and using same WO2008130551A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08742912A EP2147092A4 (en) 2007-04-16 2008-04-15 Antibiotic resistance free listeria strains and methods for constructing and using same
JP2010504068A JP2010534058A (en) 2007-04-16 2008-04-15 Listeria monocytogenes without antibiotic resistance and methods of construction and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/785,249 2007-04-16
US11/785,249 US7855064B2 (en) 2004-08-13 2007-04-16 Antibiotic resistance free vaccines and methods for constructing and using same
US11/818,965 2007-04-27
US11/818,965 US7858097B2 (en) 2004-08-13 2007-04-27 Antibiotic resistance free Listeria strains and methods for constructing and using same

Publications (2)

Publication Number Publication Date
WO2008130551A2 WO2008130551A2 (en) 2008-10-30
WO2008130551A3 true WO2008130551A3 (en) 2008-12-24

Family

ID=39876122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004861 WO2008130551A2 (en) 2007-04-16 2008-04-15 Antibiotic resistance free listeria strains and methods for constructing and using same

Country Status (2)

Country Link
EP (1) EP2147092A4 (en)
WO (1) WO2008130551A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
DK2853269T3 (en) 2008-05-19 2019-08-05 Advaxis Inc Double delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by dal / dat mutation and deletion of ActA comprising a nucleic acid molecule encoding a listeriolysine O prostate-specific antigen fusion protein
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2498808A4 (en) 2009-11-11 2014-01-08 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
MX2016010791A (en) 2014-02-18 2017-04-27 Advaxis Inc Biomarker directed multi-target immunotherapy.
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
EP3350337A4 (en) * 2015-09-15 2019-04-03 Advaxis, Inc. Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strain
CN110506107A (en) 2016-11-30 2019-11-26 阿德瓦希斯公司 Target the immunogenic composition and its application method of relapsed cancer mutation
CA3075849A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025376A1 (en) * 1997-11-18 1999-05-27 The Trustees Of The University Of Pennsylvania Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942391B1 (en) * 2004-08-13 2018-05-23 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025376A1 (en) * 1997-11-18 1999-05-27 The Trustees Of The University Of Pennsylvania Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAUER ET AL: "Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants

Also Published As

Publication number Publication date
WO2008130551A2 (en) 2008-10-30
EP2147092A2 (en) 2010-01-27
EP2147092A4 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
WO2008130551A3 (en) Antibiotic resistance free listeria strains and methods for constructing and using same
WO2006017856A3 (en) Methods for constructing antibiotic resistance free vaccines
NZ749872A (en) Compositions comprising bacterial strains
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2016090327A3 (en) Antibodies targeting b-cell maturation antigen and methods of use
EP3722412A4 (en) Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria
WO2016034591A3 (en) Mutant csgg pores
WO2016090329A3 (en) Antibodies targeting g-protein coupled receptor and methods of use
EP3124989A4 (en) Single-chip three-axis magnetic field sensor and preparation method therefor
WO2013096380A3 (en) Anti-phf-tau antibodies and their uses
MX336001B (en) Anti-axl antibodies and methods of use.
WO2012048340A3 (en) High-throughput immune sequencing
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
WO2007100908A3 (en) Chimeric adenoviral vectors
WO2012087962A3 (en) Anti-mesothelin antibodies and immunoconjugates
WO2011139973A3 (en) Methods of inhibiting fibrosis using anti-pai-1 antibodies
EP3464349A4 (en) Compositions and methods for antibodies targeting staphylococcal leukotoxins
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
MX340555B (en) Antibodies against il-18r1 and uses thereof.
EP3307772A4 (en) Tgf-beta 3 specific antibodies and methods and uses thereof
EP3565596A4 (en) Methods and compositions relating to anti-chi3l1 antibody reagents
EP3580326A4 (en) Novel probiotics bifidobacteria strains
EP3426297A4 (en) Gitr antibodies, methods, and uses
EP3279217A4 (en) Streptococcus pneumoniae protein antigen, and preparation method and use thereof
MX336323B (en) Anti-polyubiquitin antibodies and methods of use.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742912

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2010504068

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008742912

Country of ref document: EP